Stock Analysis
Celldex Therapeutics, Inc. (CLDX) Stock Analysis
Celldex Therapeutics, Inc. (CLDX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Celldex Therapeutics, Inc. (CLDX) currently has an AIQ Score of 43/100, indicating a bearish setup. Risk is the strongest factor at 55/100. Quality is the weakest current factor at 30/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
CLDX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $28.83 |
| AIQ Score | 43/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $2.26B |
| P/E Ratio (TTM) | -6.69 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.96 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.22 |
| Volume | 544.31K |
| 52-week range | $22.33-$45.14 |
| RSI 14 | 43.46 |
| 50-Day SMA | $31.98 |
| 200-Day SMA | $32.84 |
| Analyst Price Target | $69.25 |
| Next Earnings | Feb 24, 2027 |
CLDXCelldex Therapeutics, Inc.
Healthcare / Biotechnology
Low Priority
Above Peers
Latest quote
- Momentum48
- Value—
- Quality30
- Risk resilience55
- Sentiment—
CLDX Stock Analysis Summary
Celldex Therapeutics, Inc. (CLDX) currently has an AIQ Score of 43/100, indicating a bearish setup. Risk resilience is the strongest factor at 55/100. Quality is the weakest current factor at 30/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, CLDX has AIQ Score of 43/100 with Risk resilience base of 55/100 and fading Quality at 30/100. Wait for component alignment before adding exposure.
Risk resilience (55/100) leads while Quality (30/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 1.05% stock move · CLDX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is CLDX Bullish or Bearish Right Now?
CLDX currently has a bearish overall setup. Risk Resilience is the strongest factor at 55/100, while Quality is weakest at 30/100. The current evidence suggests a bearish setup.
- - Analyst target implies +140.20% upside from the latest quote.
- - Momentum is weak at 48/100.
- - Price is -12.21% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (32 vs 7).
Current Consensus
CLDX's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 7 neutral, and 32 sell votes. CLDX's 14-day RSI is 43.46, which places the stock in a weaker momentum range. CLDX's beta is 1.22, indicating greater market sensitivity than the broad market.
What Changed in CLDX?
The largest recent change in CLDX is Momentum moving up by 3.0 points over the available 7-day comparison window. Risk Resilience remains the strongest visible factor.
What Would Change the CLDX Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
CLDX Decision Framework
Public evidence layers, setup checks, and risk context for Celldex Therapeutics, Inc..
Celldex Therapeutics, Inc. (CLDX) Stock Analysis
Celldex Therapeutics, Inc. has an AIQ Score of 43/100 in a Bearish regime. Risk is strongest at 55/100. Beta is 1.22, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | CLDX is in a Bearish AIQ regime with score 43/100. |
| Signal Conflict | The primary conflict is that risk leads at 55/100 while quality lags at 30/100. |
| Factor Evidence | Momentum 48/100 · Quality 30/100 · Risk 55/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 55/100.
Momentum is 48/100 and RSI (14) is 43.5.
CLDX is in a Bearish regime at 43/100.
Risk factor is 55/100 with beta 1.22 and annual volatility 52.44%.
Current conflict: risk leads at 55/100 while quality lags at 30/100.
CLDX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
CLDX Fundamentals
CLDX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
CLDX Technical Analysis
CLDX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
CLDX Stock Catalysts
Track CLDX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
CLDX Dividend Analysis
CLDX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
CLDX Financial Data
CLDX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
CLDX Risk Analysis
CLDX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
CLDX Stock News
CLDX stock news, market tone, recent headlines, and catalyst context.
CLDX vs Biotechnology Peers
Current peer cohort: CLDX · COGT · CYTK · DFTX · DNTH. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| CLDX Current stock | 43/100 | — | 48/100 | 55/100 | 0.55 | 52.44% | Current |
| COGT Cogent Biosciences, Inc. | 44/100 | — | 45/100 | 51/100 | -0.23 | 45.96% | CLDX vs COGT |
| CYTK Cytokinetics, Incorporated | 40/100 | 41/100 | 28/100 | 56/100 | -0.23 | 43.65% | CLDX vs CYTK |
| DFTX Definium Therapeutics, Inc. | 59/100 | — | 64/100 | 44/100 | 1.61 | 77.71% | CLDX vs DFTX |
| DNTH Dianthus Therapeutics, Inc. | 56/100 | — | 58/100 | 58/100 | 1.82 | 59.79% | CLDX vs DNTH |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for CLDX: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching CLDX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for CLDX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
CLDX Stock FAQ
What is CLDX stock price today?
Celldex Therapeutics, Inc.'s current stock price is $28.83. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is CLDX bullish or bearish right now?
CLDX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is CLDX's market cap?
CLDX's market cap is $2.26B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is CLDX's current P/E ratio?
CLDX's current P/E ratio is -6.69 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is CLDX's RSI?
CLDX's 14-day RSI is 43.46 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is CLDX above its 50-day and 200-day moving averages?
CLDX is -9.85% from its 50-day SMA and -12.21% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is CLDX's next earnings date?
CLDX's next earnings date is currently listed as Feb 24, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does CLDX pay a dividend?
CLDX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.